HER2-Negative Breast Cancer – China Drug Forecast and Market Analysis to 2023

Pages: 209 Published: January 01, 2015 Report Code: GDHC355CFR

  • Overview
  • Contents
  • Tables
  • Figures
  • Listen
    iSpeech

Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-negative breast cancer market, with coverage of multiple settings; neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic. Overall five year survival in breast cancer is relatively high, at around 90%, but this is subjective to the subtype and stage of the disease. Importantly this report segments HER2 negative breast cancer into its two major subtypes; hormone receptor positive (HR+) and triple negative breast cancer (TNBC). Importantly, although substantial growth in the Chinese market is expected, it is important to consider when comparing China with the other markets, that in the base year of the forecast period (2013), it had the fewest approved branded therapies (three) of any market, and was one of the smallest markets with regard to sales. This means that modest growth from this point on can translate into an increased share of the global market in later years. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

Overview of HER2-Negative Breast Cancer including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in China including product HER2-Negative Breast Cancercription, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in China from 2013-2023.

Analysis of the impact of key events as well the drivers and restraints affecting the China HER2-Negative Breast Cancer market.

Reasons to Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for HER2-Negative Breast Cancer.

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2013-2023 in China.

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.1.3Basic Breast Anatomy

3.2Disease Classification/Staging Systems

3.3Symptoms

3.4Prognosis

3.5Quality of Life

4Disease Management

4.1Diagnosis and Treatment Overview

4.1.1Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB)

4.1.2Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIC)

4.1.3Treatment Guidelines and Leading Prescribed Drugs

4.2China

4.2.1Diagnosis

4.2.2Clinical Practice

5Competitive Assessment

5.1Overview

5.2Product Profiles (Branded Therapies)

5.2.1Abraxane (nab-paclitaxel)

5.2.2Afinitor (everolimus)

5.2.3Avastin (bevacizumab)

5.2.4Doxil/Caelyx (pegylated liposomal doxorubicin)

5.2.5Halaven (eribulin mesylate)

5.2.6Ixempra (ixabepilone)

5.2.7Xeloda (capecitabine)

5.3Product Profiles (Hormonal Agents)

5.3.1Tamoxifen

5.3.2Faslodex (fulvestrant)

5.3.3Aromatase Inhibitors

6Unmet Need and Opportunity

6.1Overview

6.1.1Defined treatment plan for BRCA mutation-positive patients and prevention of prophylactic surgeries

6.1.2Specific treatment options for TNBC patients

6.1.3Prevention of brain metastasis

6.1.4Neoadjuvant therapy that can downstage tumors

6.1.5For HR+patients, reduced resistance to hormonal agents

6.1.6Improved convenience of administration of hormonal agents

7Pipeline Assessment

7.1Overview

7.1.1Abemaciclib (LY2835219)

7.1.2Buparlisib (BKM- 120)

7.1.3Javlor (vinflunine)

7.1.4LEE011

7.1.5NeuVax (nelipepimut-S/E75)

7.1.6Niraparib (MK4827)

7.1.7NKTR- 102 (etirinotecan pegol)

7.1.8Lynparza (olaparib)

7.1.9Palbociclib (PD-0332991)

7.1.10Talazoparib (BMN 673)

7.1.11Veliparib (ABT-888)

7.2Promising Drugs in Clinical Development

7.2.1PD-/PD-L 1 Immunotherapies

8Market Outlook

8.1China

8.1.1Forecast

8.1.2Key Events

8.1.3Drivers and Barriers

9Appendix

9.1Bibliography

9.2Abbreviations

9.3Methodology

9.4Forecasting Methodology

9.4.1Diagnosed HER2-Negative Breast Cancer Patients

9.4.2Percentage of Drug-Treated Patients

9.4.3Drugs Included in Each Therapeutic Class

9.4.4Launch and Patent Expiry Dates

9.4.5General Pricing Assumptions

9.4.6Individual Drug Assumptions

9.4.7Generic Erosion

9.4.8Pricing of Pipeline Agents

9.5Primary Research – KOLs Interviewed for This Report

9.6Primary Research – High-Prescriber Survey

9.7About the Authors

9.7.1Analyst

9.7.2Director of Oncology

9.7.3Epidemiologist

9.7.4Director of Epidemiology

9.7.5Global Head of Healthcare

9.8About GlobalData

9.9Disclaimer

List of Tables

Table 1: AJCC Stage Definitions for Breast Cancer

Table 2: Prognosis for Breast Cancer

Table 3: Treatment Guidelines for HER2-Negative Breast Cancer

Table 4: Most Prescribed Regimens for HER2-Negative Breast Cancer by Drug Class in the Global Markets, 2013

Table 5: HER2-Negative Breast Cancer Diagnosis and Treatment, Country Profile – China

Table 6: Product Profile – Abraxane

Table 7: Abraxane SWOT Analysis, 2013

Table 8: Global Sales Forecast ($m) for Abraxane, 2013–2023

Table 9: Product Profile – Afinitor (everolimus)

Table 10: Afinitor SWOT Analysis, 2013

Table 11: Global Sales Forecast ($m) for Afinitor, 2013–2023

Table 12: Product Profile – Avastin

Table 13: Avastin SWOT Analysis, 2013

Table 14 Global Sales Forecast ($m) for Avastin, 2013–2023

Table 15: Product Profile – Doxil

Table 16: Doxil SWOT Analysis, 2013

Table 17: Global Sales Forecast ($m) for Doxil/Caelyx, 2013–2023

Table 18: Product Profile – Halavan

Table 19: Halaven SWOT Analysis, 2013

Table 20: Global Sales Forecast ($m) for Halaven, 2013–2023

Table 21: Product Profile – Ixempra

Table 22: Ixempra SWOT Analysis, 2013

Table 23: Global Sales Forecast ($m) for Ixempra, 2013–2023

Table 24: Product Profile – Xeloda

Table 25: Xeloda SWOT Analysis, 2013

Table 26: AI Approvals in the US and 5EU

Table 27: Unmet Need and Opportunity in HER2-Negative Breast Cancer

Table 28: Product Profile – Abemaciclib (LY2835219)

Table 29: Abemaciclib SWOT Analysis, 2013

Table 30: Global Sales Forecast ($m) for Abemaciclib, 2013–2023

Table 31: Product Profile – Buparlisib (BKM- 120)

Table 32: Buparlisib SWOT Analysis, 2013

Table 33: Global Sales Forecast ($m) for Buparlisib, 2013–2023

Table 34: Product Profile – Javlor

Table 35: Javlor SWOT Analysis, 2013

Table 36: Global Sales Forecast ($m) for Buparlisib, 2013–2023

Table 37: Product Profile – LEE011

Table 38: LEE011 SWOT Analysis, 2013

Table 39: Global Sales Forecast ($m) for LEE011, 2013–2023

Table 40: Product Profile – NeuVax

Table 41: NeuVax SWOT Analysis, 2013

Table 42: Global Sales Forecast ($m) for NeuVax, 2013–2023

Table 43: Product Profile – Niraparib

Table 44: Niraparib SWOT Analysis, 2013

Table 45: Global Sales Forecast ($m) for Niraparib, 2013–2023

Table 46: Product Profile – NKTR- 102

Table 47: NKTR-102 SWOT Analysis, 2013

Table 48: Global Sales Forecast ($m) for NKTR 102, 2013–2023

Table 49: Product Profile – Lynparza

Table 50: Lynparza SWOT Analysis, 2013

Table 51: Global Sales Forecast ($m) for Lynparza, 2013–2023

Table 52: Product Profile – Palbociclib

Table 53: Palbociclib SWOT Analysis, 2013

Table 54: Global Sales Forecast ($m) for Palbociclib, 2013–2023

Table 55: Product Profile – Talazoparib

Table 56: Talazoparib SWOT Analysis, 2013

Table 57 Global Sales Forecast ($m) for Talazoparib, 2013–2023

Table 58: Product Profile – Veliparib

Table 59: Veliparib SWOT Analysis, 2013

Table 60: Global Sales Forecast ($m) for Veliparib, 2013–2023

Table 61: Early-Stage Immunotherapies in Development for HER2-Negative Breast Cancer, 2014

Table 62: Sales Forecasts ($m) for HER2-Negative Breast Cancer in China, 2013–2023

Table 63: Key Events Impacting Sales for HER2-Negative Breast Cancer in China, 2013–2023

Table 64: Chinese HER2-Negative Breast Cancer Market – Drivers and Barriers, 2013–2023

Table 65: HER2-Negative Breast Cancer Incidence, 2013–2023

Table 66: Key Launch Dates of Marketed and Pipeline Drugs for HER2-Negative Breast Cancer

Table 67: Key Expiry Dates of Marketed and Pipeline Drugs Used in HER2-Negative Breast Cancer

Table 68: Average Body Weight and Surface Area Across the 8MM

Table 69: Cost per Treatment Cycle ($) – Abraxane, Metastatic Setting (HR+)

Table 70 Cost per Treatment Cycle ($) – Avastin, Metastatic Setting (HR+/TNBC)

Table 71: Cost per Treatment Cycle ($) – Afinitor, Third-Line Hormonal/ Targeted Therapy

Table 72: Cost per Treatment Cycle ($) – Doxil, Metastatic Setting (HR+/TNBC)

Table 73: Cost per Treatment Cycle ($) – Halaven, Metastatic Setting (HR+/TNBC)

Table 74: Cost per Treatment Cycle ($) – Ixempra, Metastatic Setting (HR+/TNBC)

Table 75 Cost per Treatment Cycle ($) – Xeloda, Metastatic Setting (HR+/TNBC)

Table 76: Cost per Treatment Cycle ($) – Abemaciclib, First-/Second-Line Hormonal/Targeted Metastatic Setting (HR+)

Table 77: Cost per Treatment Cycle ($) – Buparlisib, Postmenopausal Hormonal Neoadjuvant, Second- and Third-Line Hormonal/Targeted Metastatic Settings (HR+)

Table 78: Cost per Treatment Cycle ($) – Javlor, Third-Line Chemotherapy Metastatic Setting (HR+)

Table 79: Cost per Treatment Cycle ($) – LEE011, Postmenopausal Hormonal Neoadjuvan, and First-Line Hormonal/Targeted Metastatic Settings (HR+)

Table 80: Cost per Treatment Cycle ($) – NeuVax, Adjuvant Setting (HR+)

Table 81: Cost per Treatment Cycle ($) – Niraparib, Metastatic TNBC Setting

Table 82: Cost per Treatment Cycle ($) – NKTR-102, Third Line Chemotherapy Metastatic Setting (HR+)

Table 83: Cost per Treatment Cycle ($) – Lynparza, Adjuvant and First-Line Metastatic TNBC Settings

Table 84: Cost per Treatment Cycle ($) – Palbociclib, First- and Second-Line Hormonal/Targeted Metasatatic Setting (HR+)

Table 85: Cost per Treatment Cycle ($) – Talazoparib, Third-Line Metastatic TNBC Setting

Table 86: Cost per Treatment Cycle ($) – Veliparib, Neoadjuvant and Second-Line Metastatic TNBC Settings

Table 87: Physicians Surveyed by Country

List of Figures

Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes

Figure 2: Key Late-Stage Clinical Trials of Abraxane

Figure 3: Key Late-Stage Clinical Trials of Afinitor

Figure 4: Key Late-Stage Clinical Trials of Avastin

Figure 5: Key Late-Stage Clinical Trials of Halaven

Figure 6: Late Stage Clinical Trials of Drugs in HR+ Breast Cancer

Figure 7: Late Stage Clinical Trials of Drugs in TNBC

Figure 8: Key Late-Stage Clinical Trials of Abemaciclib

Figure 9: Clinical and Commercial Positioning of Abemaciclib

Figure 10: Key Late-Stage Clinical Trials of Buparlisib

Figure 11: Clinical and Commercial Positioning of Buparlisib

Figure 12: Key Late-Stage Clinical Trials of Javlor

Figure 13: Clinical and Commercial Positioning of Javlor

Figure 14: Key Late-Stage Clinical Trials of LEE011

Figure 15: Clinical and Commercial Positioning of LEE011

Figure 16: Key Late-Stage Clinical Trials of NeuVax

Figure 17: Clinical and Commercial Positioning of NeuVax

Figure 18: Key Late-Stage Clinical Trials of Niraparib

Figure 19: Clinical and Commercial Positioning of Niraparib

Figure 20: Key Late-Stage Clinical Trials of NKTR-102

Figure 21: Clinical and Commercial Positioning of NKTR-102

Figure 22: Key Late-Stage Clinical Trials of Lynparza

Figure 23: Clinical and Commercial Positioning of Lynparza

Figure 24: Key Late-Stage Key Clinical Trials of Palbociclib

Figure 25: Clinical and Commercial Positioning of Palbociclib

Figure 26: Key Late-Stage Clinical Trials of Talazoparib

Figure 27: Clinical and Commercial Positioning of Talazoparib

Figure 28: Key Late-Stage Clinical Trials of Veliparib

Figure 29: Clinical and Commercial Positioning of Veliparib

Figure 30: Sales for HER20Negative Breast Cancer in China by Drug, 2013–2023

$4995

Can be used by individual purchaser only

$14985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.